<p>上周，您可能看到 <strong>MediWound Ltd.</strong> (NASDAQ:MDWD) 向市场发布了其第三季度业绩。早期反应并不积极，过去一周股价下跌了 6.5%，至 17.06 美元。540 万美元的收入低于预期 17%，但至少法定亏损远低于预期，每股亏损为 0.24 美元，比分析师预测的要小 70%。收益是投资者关注的重要时刻，因为他们可以跟踪公司的表现，查看分析师对明年的预测，并观察对公司的情绪是否发生变化。因此，我们收集了最新的财报后预测，以了解估计值对明年的展望。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1570881-earnings-and-revenue-growth-1-dark-2/1763900160397?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1570881-earnings-and-revenue-growth-1-dark-2/1763900160397"/></p>
<p>NasdaqGM:MDWD 收益和收入增长 2025 年 11 月 23 日</p>
<p>考虑到最新的业绩，MediWound 六位分析师的当前共识是 2026 年的收入为 2880 万美元。这将反映出过去 12 个月收入的 38% 的显著增长。每股亏损预计将激增，达到每股 2.48 美元。然而，在最新财报发布之前，分析师们曾预测 2026 年的收入为 2960 万美元，每股亏损为 2.50 美元。</p>
<p>查看我们对 MediWound 的最新分析</p>
<p>平均目标价 31.50 美元没有实质性变化，这表明收入预期的修订预计不会对 MediWound 的估值产生长期影响。共识目标价只是各个分析师目标的平均值，因此——了解基础估计的范围可能会很有帮助。目前，最乐观的分析师将 MediWound 的每股价值定为 39.00 美元，而最悲观的分析师则定为 25.00 美元。这表明估计值之间仍然存在一定的差异，但分析师们似乎并没有完全分歧，认为该股票可能会成功或失败。</p>
<p>获取这些预测的更多背景信息的一种方法是查看它们与过去表现的比较，以及同一行业其他公司的表现。这些估计中有一点突出，即 MediWound 预计未来的增长速度将快于过去，预计到 2026 年底收入将显示出 29% 的年化增长。如果实现，这将比过去五年的 3.2% 的年均下降要好得多。与分析师对更广泛行业的估计相比，后者预计（总体上）行业收入将年均增长 9.5%。不仅 MediWound 的收入预计将改善，分析师们似乎也预计其增长速度将快于更广泛的行业。</p>
<h2>结论</h2>
<p>最明显的结论是，分析师们对明年的亏损预测没有做出任何更改。遗憾的是，他们还下调了收入预期，但最新的预测仍然暗示该业务将比更广泛的行业增长得更快。共识目标价没有实质性变化，这表明该业务的内在价值在最新估计中没有发生重大变化。</p>
<p>考虑到这一点，我们不应过快得出关于 MediWound 的结论。长期的盈利能力远比明年的利润更为重要。在 Simply Wall St，我们有一系列到 2027 年的 MediWound 分析师估计，您可以在我们的平台上免费查看。</p>
<p>此外，您还应该了解我们发现的 MediWound 的 <strong>2 个警告信号</strong>。</p>

MDWD

<p>MediWound Ltd.（纳斯达克代码：MDWD）发布了其第三季度业绩，显示股价下跌 6.5%，收入为 540 万美元，低于预期 17%。然而，每股亏损比预期小 70%。分析师预测 2026 年收入为 2880 万美元，增长 38%，每股亏损为 2.48 美元。尽管收入下调，但共识目标价仍为 31.50 美元，表明估值没有重大变化。预计 MediWound 的增长速度将快于行业，直到 2026 年年化增长率为 29%，而行业的年化增长率为 9.5%</p>

<p>Last week, you might have seen that <strong>MediWound Ltd.</strong> (NASDAQ:MDWD) released its third-quarter result to the market. The early response was not positive, with shares down 6.5% to US$17.06 in the past week. Revenues of US$5.4m missed forecasts by 17%, but at least statutory losses were much smaller than expected, with per-share losses of US$0.24 coming in 70% smaller than what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.</p>
<div class="lb-trans"><p>上周，您可能看到 <strong>MediWound Ltd.</strong> (NASDAQ:MDWD) 向市场发布了其第三季度业绩。早期反应并不积极，过去一周股价下跌了 6.5%，至 17.06 美元。540 万美元的收入低于预期 17%，但至少法定亏损远低于预期，每股亏损为 0.24 美元，比分析师预测的要小 70%。收益是投资者关注的重要时刻，因为他们可以跟踪公司的表现，查看分析师对明年的预测，并观察对公司的情绪是否发生变化。因此，我们收集了最新的财报后预测，以了解估计值对明年的展望。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1570881-earnings-and-revenue-growth-1-dark-2/1763900160397" alt="" original-src="https://images.simplywall.st/asset/chart/1570881-earnings-and-revenue-growth-1-dark-2/1763900160397"/></p>
<p>NasdaqGM:MDWD Earnings and Revenue Growth November 23rd 2025</p>
<div class="lb-trans"><p>NasdaqGM:MDWD 收益和收入增长 2025 年 11 月 23 日</p>
</div><p>Taking into account the latest results, the current consensus from MediWound's six analysts is for revenues of US$28.8m in 2026. This would reflect a sizeable 38% increase on its revenue over the past 12 months. Per-share losses are expected to explode, reaching US$2.48 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$29.6m and losses of US$2.50 per share in 2026.</p>
<div class="lb-trans"><p>考虑到最新的业绩，MediWound 六位分析师的当前共识是 2026 年的收入为 2880 万美元。这将反映出过去 12 个月收入的 38% 的显著增长。每股亏损预计将激增，达到每股 2.48 美元。然而，在最新财报发布之前，分析师们曾预测 2026 年的收入为 2960 万美元，每股亏损为 2.50 美元。</p>
</div><p>See our latest analysis for MediWound</p>
<div class="lb-trans"><p>查看我们对 MediWound 的最新分析</p>
</div><p>There was no real change to the average price target of US$31.50, suggesting that the revisions to revenue estimates are not expected to have a long-term impact on MediWound's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values MediWound at US$39.00 per share, while the most bearish prices it at US$25.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.</p>
<div class="lb-trans"><p>平均目标价 31.50 美元没有实质性变化，这表明收入预期的修订预计不会对 MediWound 的估值产生长期影响。共识目标价只是各个分析师目标的平均值，因此——了解基础估计的范围可能会很有帮助。目前，最乐观的分析师将 MediWound 的每股价值定为 39.00 美元，而最悲观的分析师则定为 25.00 美元。这表明估计值之间仍然存在一定的差异，但分析师们似乎并没有完全分歧，认为该股票可能会成功或失败。</p>
</div><p>One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. One thing stands out from these estimates, which is that MediWound is forecast to grow faster in the future than it has in the past, with revenues expected to display 29% annualised growth until the end of 2026. If achieved, this would be a much better result than the 3.2% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 9.5% annually. Not only are MediWound's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.</p>
<div class="lb-trans"><p>获取这些预测的更多背景信息的一种方法是查看它们与过去表现的比较，以及同一行业其他公司的表现。这些估计中有一点突出，即 MediWound 预计未来的增长速度将快于过去，预计到 2026 年底收入将显示出 29% 的年化增长。如果实现，这将比过去五年的 3.2% 的年均下降要好得多。与分析师对更广泛行业的估计相比，后者预计（总体上）行业收入将年均增长 9.5%。不仅 MediWound 的收入预计将改善，分析师们似乎也预计其增长速度将快于更广泛的行业。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.</p>
<div class="lb-trans"><p>最明显的结论是，分析师们对明年的亏损预测没有做出任何更改。遗憾的是，他们还下调了收入预期，但最新的预测仍然暗示该业务将比更广泛的行业增长得更快。共识目标价没有实质性变化，这表明该业务的内在价值在最新估计中没有发生重大变化。</p>
</div><p>With that in mind, we wouldn't be too quick to come to a conclusion on MediWound. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for MediWound going out to 2027, and you can see them free on our platform here..</p>
<div class="lb-trans"><p>考虑到这一点，我们不应过快得出关于 MediWound 的结论。长期的盈利能力远比明年的利润更为重要。在 Simply Wall St，我们有一系列到 2027 年的 MediWound 分析师估计，您可以在我们的平台上免费查看。</p>
</div><p>Plus, you should also learn about the <strong>2 warning signs</strong> we've spotted with MediWound .</p>
<div class="lb-trans"><p>此外，您还应该了解我们发现的 MediWound 的 <strong>2 个警告信号</strong>。</p>
</div>

MediWound Ltd.（纳斯达克代码：MDWD）第三季度业绩已公布，分析师们发布了新的预测